AAP
SGMT icon

Arax Advisory Partners’s Sagimet Biosciences SGMT Stock Holding History

Arax Advisory Partners’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$601 Hold
115
– – ﹤0.01% 3390
2025
Q4 		$681 Hold
115
– – ﹤0.01% 3556
2025
Q3 		$789 Buy
+115
New +$933 ﹤0.01% 3303
2025
Q1 		– Sell
-115
Closed -$518 – 3005
2024
Q4 		$518 Hold
115
– – ﹤0.01% 2321
2024
Q3 		$319 Hold
115
– – ﹤0.01% 2464
2024
Q2 		$394 Buy
+115
New +$528 ﹤0.01% 2358

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arax Advisory Partners's SGMT Position: Q1 2026 in Review

Arax Advisory Partners held its Sagimet Biosciences (SGMT) position steady in Q1 2026 at 115 shares worth $601. The position accounts for ﹤0.01% of the portfolio, ranked #3390.

Arax Advisory Partners first reported a position in SGMT in Q2 2024 and has held it in 6 quarters since. The position peaked at $789 in Q3 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Arax Advisory Partners held 115 shares of Sagimet Biosciences worth $601 as of Q1 2026.
  • Arax Advisory Partners left its Sagimet Biosciences share count unchanged in Q1 2026.
  • Sagimet Biosciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3390 holding.
  • Arax Advisory Partners first reported a position in Sagimet Biosciences in Q2 2024 and has held it in 6 quarters since.
  • Arax Advisory Partners's Sagimet Biosciences position peaked at $789 in Q3 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.